A dose escalating phase I study of GLPG0187, a broad spectrum integrin receptor antagonist, in adult patients with progressive high-grade glioma and other advanced solid malignancies

Background Integrin signaling is an attractive target for anti-cancer treatment. GLPG0187 is a broad spectrum integrin receptor antagonist (IRA). GLPG0187 inhibited tumor growth and metastasis in mouse models. Methods We aimed to determine the Recommended Phase II Dose (RP2D) and to assess safety an...

Descripción completa

Detalles Bibliográficos
Autores principales: Cirkel, Geert A., Kerklaan, Bojana Milojkovic, Vanhoutte, Frédéric, der Aa, Annegret Van, Lorenzon, Giocondo, Namour, Florence, Pujuguet, Philippe, Darquenne, Sophie, de Vos, Filip Y. F., Snijders, Tom J., Voest, Emile E., Schellens, Jan H. M., Lolkema, Martijn P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2016
Materias:
Phase I Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4786599/
https://www.ncbi.nlm.nih.gov/pubmed/26792581
http://dx.doi.org/10.1007/s10637-015-0320-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4786599/
https://www.ncbi.nlm.nih.gov/pubmed/26792581
http://dx.doi.org/10.1007/s10637-015-0320-9

Ejemplares similares